IPP Bureau
Myovant Sciences and Accord Healthcare partner to commercialise Orgovyx in Europe
By IPP Bureau - May 10, 2022
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
Cipla launches ‘RT Direct’ Multiplex real-time PCR kit for Covid-19
By IPP Bureau - May 10, 2022
RNA extraction free kit to deliver results in just 45 minutes
Roche extends commitment to the World Federation of Hemophilia Humanitarian Aid Program
By IPP Bureau - May 10, 2022
The renewed commitment will provide continued preventative (prophylactic) treatment to as many as 1,000 people with haemophilia A in locations where there is little to no access to haemophilia treatment
Indian Pharma Market slips for third month in a row: Anand Rathi
By IPP Bureau - May 10, 2022
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
Sun gets 10 observations from USFDA for Halol facility
By IPP Bureau - May 10, 2022
The company is preparing the response to the observations, which will be submitted to the USFDA within 15 business days
Emcure launches EmWocal campaign to raise women’s health issues
By IPP Bureau - May 10, 2022
The campaign will be available in nine Indian languages namely Hindi, English, Odia, Marathi, Tamil, Telugu, Kannada, Malayalam and Bengali
Novo Nordisk and Flagship Pioneering partner to create a portfolio of transformational medicines
By IPP Bureau - May 10, 2022
Pioneering Medicines and Novo Nordisk Bio Innovation Hub will leverage Flagship Pioneering’s bioplatform companies to create a portfolio of research programmes within cardiometabolic and rare diseases
Lonza, ALSA Ventures collaborate on providing manufacturing services to biotech firms
By IPP Bureau - May 10, 2022
The new framework collaboration will support due diligence into ALSA’s potential investments, which will assist with their investment de-risking
Omega Healthcare to expand operations in India
By IPP Bureau - May 10, 2022
Omega plans to further strengthen its capabilities, deepen domain expertise and build new solutions
Bora Pharmaceuticals acquires Eden Biologics CDMO assets
By IPP Bureau - May 10, 2022
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
CEPI partners with Bharat Biotech, Unversity of Sydney and ExcellGene to develop variant proof Covid-19 vaccine
By IPP Bureau - May 10, 2022
CEPI will provide funding of up to US $19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium
Pfizer to acquire Biohaven Pharmaceuticals for US $ 11.6 billion
By IPP Bureau - May 10, 2022
Pfizer to commercialize NURTEC ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need
Glenmark receives tentative ANDA approval for Calcipotriene and Betamethasone Dipropionate
By IPP Bureau - May 09, 2022
Glenmark's current portfolio consists of 174 products authorized for distribution in the U.S. marketplace and 48 ANDA's pending approval with the USFDA
InxMed raises US $ 15 million in Series B+ financing
By IPP Bureau - May 09, 2022
The plan is to advance innovative therapies to drug-resistant cancers
ExoCoBio receives Japanese patent for alleviating dermatitis
By IPP Bureau - May 09, 2022
To lay a technological foundation for developing exosome-based medicines and cosmetic products for dermatitis treatment
